(Q35095221)

6 August 2017

1 reference

title

Docetaxel in non-small cell lung cancer: a review (English)

1 reference

6 August 2017

1 reference

1 reference

4

David R Gandara

1 reference

6 August 2017

Angela M Davies

1

1 reference

6 August 2017

Primo N Lara

series ordinal

2

1 reference

6 August 2017

Philip C Mack

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

553-565

1 reference

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

21 January 2018

Life and death by p53.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Mechanism of action of taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Mechanisms of taxotere-related drug resistance in pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

21 January 2018

Oral delivery of taxanes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Progress in the development of alternative pharmaceutical formulations of taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.4.553

21 January 2018

Identifiers

DOI

10.1517/14656566.4.4.553

1 reference

6 August 2017

1 reference